Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD133 liver cancer cells were injected into mice, and the tissues were processed for histology.
|
31646784 |
2020 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
We observed that Cygb is significantly deregulated in human hepatocellular carcinoma (HCC) tissue and its decrease aggravates the growth of liver cancer stem cells (LCSCs) and increases the subpopulation of CD133(+) LCSCs.
|
30365183 |
2019 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD133, a widely known liver cancer stem cell marker, plays critical roles in the maintenance of liver cancer stemness.
|
31197130 |
2019 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
This data demonstrates that the complex involvement of TIPRL/LC3/CD133 in liver cancer aggressiveness can together or individually serve as potential biomarkers for the early detection of liver cancer.
|
31727942 |
2019 |
Malignant neoplasm of liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we revealed that the expression of liver cancer stem cell marker CD133 was also significantly increased in the residual hepatocellular carcinoma cells after RFA treatment in vivo, and was positively correlated with LC3B protein expression. iRFA also promoted CD133 protein expression in Huh-7 and SMMC7721 cell lines in vitro.
|
29749472 |
2018 |
Malignant neoplasm of liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Altogether, CD133-induced TM4SF5 expression and function were important for liver cancer sphere growth and may be a promising target to block metastasis.
|
30217560 |
2018 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Down-regulating Bmi-1 may inhibit the biological properties of CD133+ LCSC by blocking NF-κB signaling pathway, which lays a scientific foundation for the clinical treatment of liver cancer.
|
29843222 |
2018 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, we investigated the role of ELK3 in cancer cell invasion and metastasis in CD133+/CD44+ liver cancer stem cells (LCSCs).
|
27959451 |
2017 |
Malignant neoplasm of liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we found that oxidative stress increase CD133 expression in HCC and increased CD133 expression enhanced the capacity of the defense system against ROS, and thereby play a central role in resistance to liver cancer therapy.
|
28253902 |
2017 |
Malignant neoplasm of liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Systems approach to characterize the metabolism of liver cancer stem cells expressing CD133.
|
28367990 |
2017 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD133+ liver cancer stem cells resist interferon-gamma-induced autophagy.
|
26758620 |
2016 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Also, CXCR3-A suppressed the adhesion ability of CD133+ liver cancer cells that stimulated by CXCL9 for 24h.
|
26883105 |
2016 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Potential Role of CD133 Expression in the Susceptibility of Human Liver Cancer Stem-Like Cells to TRAIL.
|
28281970 |
2016 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that enhanced glycolysis is associated with CD133 (+) stem-like characteristics and that metabolic reprogramming through miR-122 or PDK4 may represent a novel therapeutic approach for the treatment of hepatocellular cancer.
|
26506419 |
2015 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD133 is a specific surface marker for liver cancer stem cells (LCSCs), which is also considered as an important functional factor for tumorigenesis and overall survival in HCC.
|
26370320 |
2015 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mir-152 inhibits cell proliferation and colony formation of CD133(+) liver cancer stem cells by targeting KIT.
|
25311946 |
2015 |
Malignant neoplasm of liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Inhibitory effects of transcription factor Ikaros on the expression of liver cancer stem cell marker CD133 in hepatocellular carcinoma.
|
25301737 |
2014 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Knockdown of 14-3-3ζ enhances radiosensitivity and radio-induced apoptosis in CD133(+) liver cancer stem cells.
|
24556826 |
2014 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present report we describe the differential DNA methylome of CD133-negative and CD133-expressing liver cancer cells.
|
24898317 |
2014 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells.
|
23233126 |
2013 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Biology and clinical implications of CD133(+) liver cancer stem cells.
|
22999864 |
2013 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells.
|
23438193 |
2013 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
The stem cell properties of CD133(+) SFCs were validated by the tumorsphere formation assay in vitro and the xenograft nude mouse model in vivo, and termed liver cancer stem cells (LCSCs).
|
24431896 |
2013 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we aimed to isolate and characterize a small population of CD133+ cells that existed in the HCC cell line SMMC-7721 by MACS and investigated the possible roles of 8-bromo-7-methoxychrysin (BrMC), a synthetic analogue of chrysin, in inhibiting the properties of CD133+ sphere-forming cells (SFCs) derived from the HCC cell line SMMC-7721, namely liver cancer stem cells (LCSCs).
|
23970349 |
2013 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocellular carcinoma.
|
22773665 |
2012 |